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ABSTRACT
Background: A great interest has been dedicated to the development of non invasive predictive models in 
recent years to substitute liver biopsy for fibrosis assessment and follow-up. The aim of this study was to compare 
the accuracy between S-index and aspartate aminotransferase to platelet ratio index (APRI) to FibroScan for 
predicting liver fibrosis in chronic hepatitis B and C patients.
Method: A cross-sectional study was conducted in 40 patients with chronic hepatitis B and C between January 
2010 - May 2011 at Division of Gastroentero-hepatology, Department of Internal Medicine, Adam Malik Hospital, 
Medan. Patients underwent laboratory examination and FibroScan, then used predictive values to assess the 
accuracy of S-index scores and APRI compared to FibroScan. The analysis was performed using SPSS 15.0.
Results: S-index identified significant fibrosis in 87.5% patients with sensitivity (Se) 87.5% and specificity (Sp) 
100%. About 67.5% of 40 patients could be identified correctly. S-index also could accurately predict the absence 
or presence of cirrhosis in 87.5% of the total 40 patients, with NPV 91.7% and PPV 81.25%, respectively. APRI 
for significant fibrosis has Se 85.7%, Sp 88%, PPV 88.8%, NPV 69.2%; while Se 53%, Sp 88%, PPV 72.7%, 
NPV 75.8% for liver cirrhosis. AUROC value for S-index was higher than APRI in predicting significant fibrosis 
and cirrhosis, i.e. 0.938 vs. 0.917 and 0.873 and 0.707, respectively. 
Conclusion: The S-index has a higher accuracy than APRI in predicting significant fibrosis and cirrhosis in 
patients with chronic hepatitis B virus and hepatitis C virus infection.
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ABSTRAK
Latar belakang: Minat yang besar didedikasikan untuk pengembangan model prediksi non invasif dalam 
beberapa tahun terakhir untuk menggantikan biopsi hati dalam penilaian fibrosis beserta tindak lanjutnya. 
Tujuan penelitian ini adalah untuk membandingkan akurasi antara S-indeks dan aspartate aminotransferase to 
platelet index (APRI) dengan FibroScan untuk memprediksi fibrosis hati pada pasien hepatitis B dan C kronis.
Metode: Dilakukan penelitian potong lintang pada 40 pasien hepatitis B dan C kronik sejak Januari 2010 
sampai Mei 2011 di Divisi Gastroentero-hepatologi Departemen Ilmu Penyakit Dalam, Rumah Sakit Adam 
Malik Medan. Terhadap pasien dilakukan pemeriksaan laboratoriun dan FibroScan serta dibandingkan derajat 
akurasi skor S-indeks dan APRI. Analisis data dilakukan dengan menggunakan SPSS 15.0.
Hasil: S-indeks mengindentifikasi fibrosis signifikan pada 87,5% pasien dengan sensitifitas (Se) 87,5% dan spesifitas 
(Sp) 100%. Sejumlah 67,5% dari 40 pasien dapat diidentifikasi dengan baik. S-indeks juga dapat secara akurat 
memprediksi ada tidaknya sirosis pada 87,5% dari 40 pasien dengan NPV 91,7% dan  PPV 81,25%. APRI memprediksi 
fibrosis signifikan dengan Se 85,7%, Sp 88%, PPV 88,8%, NPV 69,2%; dimana pada pasien sirosis hati didapat Se 
53%, Sp 88%, PPV 72,7% dan NPV 75,8%. Nilai AUROC lebih tinggi pada S-indeks dibandingkan pada APRI dalam 
memprediksi baik fibrosis signifikan maupun sirosis yaitu masing-masing 0,938 vs. 0,917 serta 0,873 dan 0,707. 
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Simpulan: S-indeks memiliki akurasi yang lebih tinggi dibandingkan APRI dalam memprediksi fibrosis 
signifikan dan sirosis pada pasien dengan infeksi hepatitis B dan C kronik.
 
Kata kunci: S-indeks, skor APRI, FibroScan, hepatitis B dan C kronik
INTRODUCTION
Chronic liver disease is a global issue today as 
it often leads to liver cirrhosis and hepatocellular 
carcinoma, which is initially characterized by fibrosis 
in the liver.1,2,3 Liver fibrosis occurs due to chronic 
damage to the liver, which is associated with excessive 
accumulation of extracellular matrix protein.1,2,3,4,5 
The main etiologies of liver fibrosis include chronic 
infection of hepatitis B and C virus, alcohol drinks, 
and non-alcoholic steato hepatitis (NASH).1,6,7,8 The 
accumulation of extracellular matrix protein will distort 
liver architectures by forming fibrous connective tissue 
and resulting in the development of nodules. When the 
nodules have been developed, the condition is defined 
as cirrhosis.1,2,9,10,11,12
Liver biopsy, an invasive method, is still regarded 
as the gold standard for determining the stage of 
fibrosis. As there are so many obstacles, complication 
and expensive cost of the invasive method, numerous 
studies have proposed a diagnostic method for fibrosis 
staging using non-invasive methods.4,7,9 Liver fibrosis 
can be measured by FibroScan significantly, in 
consistent with or equal to the liver staging made by 
liver biopsy. The diagnostic accuracy of FibroScan is 
higher compared to biomarkers to evaluate the stage 
of liver fibrosis.13,14 FibroScan offers some advantages 
compared to liver biopsy since it is a rapid and painless 
test with less interpretation error.13,14
Evaluation of liver fibrosis using non-invasive 
method may also be done by APRI score and S-index. 
By comparing some of simple laboratory markers, the 
methods can predict patients with chronic liver disease. 
The aim of this study was to compare the accuracy 
of predictive value between S-index and aspartate 
aminotransferase to platelet ratio index (APRI) to 
FibroScan for predicting liver fibrosis in patients with 
chronic hepatitis B and C.
METHOD
A cross-sectional study was conducted in 40 
patients, who had been diagnosed with chronic 
hepatitis B and C and underwent FibroScan test at 
Division of Gastroentero-hepatology, Department of 
Internal Medicine, Adam Malik Hospital Medan. The 
serum of patients was collected between January 2010 
and May 2011.
The following markers were analyzed, including 
aspartate transaminase (AST), g-glutamyltransferase 
(GGT), platelets (PLT) and albumin (ALB) level, as 
well as S index score and APRI. The stage of liver 
fibrosis was determined and scored based on a scale 
of F0 to F4 using FibroScan. Predictive values were 
subsequently determined to assess the accuracy of 
S-index scores and APRI. The formula to calculate 
the score was: 
S-index = 1,000 x GGT/(PLT x ALB2)
Table 1. Cut off points of S-index 
Stages Absence Presence
Significant fibrosis (F2-4) < 0.1 ≥ 0.5
Advanced fibrosis (F3-4) < 0.2 ≥ 0.6
Cirrhosis < 0.3 ≥ 1.5
Units of measurement in the formula: GGT (IU/L); 
PLT (109/L); ALB (g/L)
APRI = AST level (U/L) / upper normal limit of AST (U/L) x100
                              Platelets (109/L)
Cut-off points of APRI: score < 0.5 = non fibrosis; 0.5– 
1.5 = mild fibrosis; score > 1.5 = cirrhosis. Cut-off point 
of FibroScan were determined according to Ledingen V, 
i.e.: F0-1 = 0–7.1 kPa; F2 ≥ 7.1–9.3 kPa; F3 ≥ 9.3–14.5 
kPa; F4 ≥ 14.5 kPa.15
Inclusion criteria of this study were patients with 
chronic liver disease caused by hepatitis B and C 
viruses with positive viral marker result, male and 
female patients aged 18 years or over and willing to 
participate in the study; while the exclusion criteria 
were co-infection with HIV, alcohol drinks of > 30 g/
day, other causes of chronic liver disease and patients 
with renal failure. 
To determine diagnostic value of S-index panel 
marker, an evaluation was performed based on receiver 
operating characteristic (ROC) curve analysis as well as 
evaluate the sensitivity (Se), specificity (Sp), positive 
predictive value (PPV), negative predictive value 
(NPV), diagnostic accuracy (DA), positive likelihood 
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ratios (LR+) and negative likelihood ratios (LR-), which 
were calculated based on cut-off points mentioned in its 
original publication and journals. Statistical analysis was 
performed using SPSS version 15.0
RESULTS
Table 2. Baseline data of patients
Variable n (%)
Sex 
Male 23 (57.5)
Female 17 (42.5)
Age (year)* 48.5 (SD ± 12.70)
Platelets (109/L )* 153.0 (SD ± 84.6)
Albumin** 3.75 (2.0 – 3.90)
Gamma GT** 55 (12 – 371)
S index** 57 (1.97 – 330.47)
APRI score** 0.91 (0.17 – 13.41)
FibroScan** 12.5 (4.30 – 69.2)
Based on normality test of Kolmogorov – Smirnov; *data of age and platelets 
have normal distribution (mean, SD); **abnormal distribution (median, min – 
max); APRI: aspartate aminotransferase to platelet ratio index
Table 3. Staging of liver fibrosis based on S-index and APRI 
Degree of fibrosis S-indexn (%)
APRI index
n (%)
Non significant fibrosis 19 (47.5%) 13 (32.5%)
Significant fibrosis 5 (12.5%) 16 (40%)
Advanced fibrosis 13 (32.5%) 0 (0%)
Cirrhosis 3 (7.5%) 11 (27.5%)
Total 40 (100%) 40 (100%)
APRI: aspartate aminotransferase to platelet ratio index
Table 4. Staging of liver fibrosis based on FibroScan in 
accordance with sex 
Sex
FibroScan
Total
n (%)Non Sig 
Fib Sig Fib Adv Fib Cirrhosis
Male 6  (50%)
2  
(50%)
5  
(56.6%)
10 
(66.7%)
23 
(57.5%)
Female 6  (50%)
2  
(50%)
4  
(44.4%)
5  
(33.3%)
17 
(42.5%)
Total 12 (100%)
4 
(100%)
9  
(100%)
15  
(100%)
40 
(100%)
Sig: significant; Fib: fibrosis; Adv: advance 
Figure 2. ROC curve of S-index to predict significant fibrosis 
with sensitivity 95%, specificity 100%, positive predictive value 
100%, negative predictive value 93.7% and AUROC 0.976
Figure 3. ROC curve of S-index and APRI to predict 
significant fibrosis of 0.938 and 0.917, respectively with 
sensitivity 86.67%, specificity 88%, positive predictive value 
81.25%, negative predictive value 91.7%, and AUROC = 0.873 
Table 5 demonstrates sensitivity 85.7%, specificity 
88%, PPV 88.8% and NPV 69.2%.
Figure 1. ROC curve of S-index to predict significant fibrosis 
with sensitivity 87.5%, specificity 100%, positive predictive 
value 100%, negative predictive value 66.7% and AUROC 0.938
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Table 6 demonstrates sensitivity 53%, specificity 
88%, PPV 72.7%, and NPV 75.8%.
Table 6. APRI predictive value for diagnosis of cirrhosis 
Cirrhosis APRI
FibroScan significant
Total
Non Sig Fib Sig Fib 
Non cirrhosis APRI 22 7 29
Cirrhosis APRI 3 8 11
Total 25 15 40
APRI: aspartate aminotransferase to platelet ratio index; Sig: significant; 
Fib: fibrosis
Figure 4. ROC curve of S-Index and APRI to predict cirrhosis 
of 0.873 and 0.707, respectively
hepatitis C and only several data available on the 
application of the non invasive method for patients with 
chronic hepatitis B. Liver biopsy has some limitations 
as a diagnostic method as it is an invasive, expensive 
method that may cause inconvenience for patients as 
well as intra- and inter observer variations. The use of 
some non-invasive diagnostic methods for diagnosing 
fibrosis and liver cirrhosis have been validated since 
2001.16,17
APRI scoring system and S-index are relatively 
inexpensive and simple method that can be easily 
performed by clinicians. S-index alone had successfully 
identified significant fibrosis in 87.5% patients with 
sensitivity 87.5% and specificity 100%, PPV 100%, 
NPV 66.7%, AUROC 0.938. Together with APRI, 
about 67.5% of the total 40 patients could be identified 
correctly; only 7.5% were misidentified by S-index and 
25% remained uncertain. S-index also could accurately 
predict the absence or presence of cirrhosis in 87.5% 
of the total 40 patients, with NPV 91.7% and PPV 
81.25%. 
The results of this study are almost similar with 
previous study conducted by Zhou et al in 2010, which 
demonstrated cut-off point of S-index for significant 
fibrosis absence < 0.1 with sensitivity 94.12%, 
specificity 42.31%, PPV 58.72%, NPV 89.19%; while 
the cut-off point for significant fibrosis presence was 
> 0.5 with sensitivity 42.65%, specificity 94.87%, 
PPV 87.88%, NPV 65.49% and AUROC 0.812. 
Furthermore, the study also showed that the cut-off 
point for cirrhosis absence was < 0.3 with sensitivity 
80%, specificity 72.52%, PPV 25% and NPV 96.94%; 
while the cut-off point for cirrhosis presence was > 
1.5 with sensitivity 53.33%, specificity 98.47%, PPV 
80.00%, NPV 94.85% and AUROC 0.890.4
The results of this study showed higher sensitivity 
and specificity compared to previous studies. A meta-
analysis conducted on some report of studies indicated 
that APRI cut-off point of 0.5 had 81% sensitivity 
and 50% specificity to predict significant fibrosis 
(F ≥ 2, Metavir score) and with cut-off point of 1, it 
had sensitivity 76% and specificity 71% to predict 
cirrhosis.6,20,21
The result of study conducted by Del Castillo et 
al showed that APRI score could be used to predict 
significant fibrosis in patients with chronic hepatitis C, 
the delimited APRI value on AUC was 0.776 (95% CI = 
0.704 - 0.847; p < 0.01); with limit threshold of  0.6433, 
they found sensitivity 74.7%, specificity 67.9%, PPV 
70.5%, NPV 72.4% with accuracy 71.3%, PLR 2.33 
(1.66 - 3.27); for cirrhosis, the APRI score on AUC 
Table 5. APRI predictive value for significant diagnosis of 
fibrosis 
APRI
FibroScan significant
Total
Non Sig Fib Sig Fib 
Sig Fib APRI Non Sig APRI 9 4 13
Sig Fib APRI 3 24 27
Total 12 28 40
APRI: aspartate aminotransferase to platelet ratio index; Sig: significant; 
Fib: fibrosis
Overall, the APRI in this study could predict 
significant fibrosis with sensitivity 85.7%, specificity 
88%, PPV 88.8% and NPV 69.2%. In patients with 
cirrhosis, the APRI had sensitivity 53%, specificity 88%, 
PPV 72.7% and NPV 75.8%. AUROC value for S-index 
was higher compared to APRI in predicting significant 
fibrosis and cirrhosis, i.e. 0.938 vs. 0.917, 0.873 and 
0.707, respectively. 
DISCUSSION 
In the last few years, some studies on non-invasive 
diagnostic method for liver fibrosis in patients with 
chronic liver disease have been published. Most of 
the studies were conducted in patients with chronic 
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was 0.830 (95% CI = 0.765 - 0.895) with a threshold 
of 0.7532, sensitivity 89.4%, specificity 70.90%, PPV 
55.3%, NPV 94.3%, accuracy 76.2% and PLR 3.08 
(2.28 - 4.15).22
A study conducted by Zhou et al showed that the 
APRI score for predicting significant fibrosis had 
cut-off point of ≤ 0.5 to predict the absence with 
sensitivity 82.35%, specificity 38.46%, PPV 53.85%, 
NPV 71.45% ; while to predict the presence, the cut-off 
point was  > 1.5 with sensitivity 48.53%, specificity 
85.90%, PPV 75%, NPV 66.60% with AUROC 0.717.4
A study about APRI conducted by Bota et al 
indicated sensitivity 67.7%, specificity 70%, PPV 
95.5%  and NPV 70% with accuracy 67.7% to predict 
significant fibrosis; while in predicting the cirrhosis, 
they found 80% sensitivity, 74.1%, specificity, 33.8% 
PPV, 95.7% NPV and 75% accuracy.19
Varied results in this study compared to previous 
study may be due to differences in cut-off point to 
determine the stage of fibrosis as well as differences 
of AUC value and basic characteristic parameter used 
in our study. The results of this study showed that 
S-index had high accuracy as a non-invasive method 
to evaluate fibrosis staging and cirrhosis compared to 
APRI scoring system. 
The study has several limitations since we did not 
perform liver biopsy as the gold standard for evaluating 
the stage of liver fibrosis and there was only one operator 
performing FibroScan; therefore there was greater 
difficulty to evaluate inter- and intraobserver variation.
CONCLUSION
S-index is a simple mathematical model containing 
routine laboratory markers, which has a higher 
accuracy when compared to APRI in predicting 
significant fibrosis and cirrhosis in patients with 
chronic HBV and HCV infection with a high degree 
of accuracy. 
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